Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
In an utterly unsurprising announcement from the UK, the National Institute for Clincial Excellence (NICE) has issued draft guidance in which it refuses to cover the proposed cost of abiraterone actetate.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cost, NICE, UK, Zytiga | 6 Comments »
An analysis of data on treatment of nearly 137,500 men treated for prostate cancer between 1991 and 2007 has suggested that permanent seed brachytherapy may be safer, less costly, and at least as effective as any other widely available form of first-line therapy for men with low- and intermediate-risk prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, complications, cost, external beam, first line, radiation, radical prostatectomy, Treatment | 3 Comments »
From a health economics point of view, prostate cancer costs a lot of money every year — because a lot of men get diagnosed and treated.
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, cost, cost-effectiveness | 3 Comments »
An article in today’s New York Times will be a red rag to the advocates for proton beam radiation therapy (PBRT).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: cost, outcome, PBRT, proton beam radiation therapy | 3 Comments »
As one might expect, there is an extremely diverse (and conflicting) range of reactions to the USPSTF recommendation that routine PSA testing of uninformed men is not supported by good evidence and should no longer be considered as appropriate “standard” practice unless there has been a prior discussion of the risks and benefits of the [...]
Filed under: Diagnosis, Management, Risk | Tagged: benefit, cost, coverage, PSA, risk, USPSTF | 6 Comments »
According to a report in today’s Daily Telegraph, the UK’s National Institute for Health and Clinical Excellence (NICE) has determined that “cabazitaxel would not be a cost effective use of limited NHS resources” for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Management, Treatment | Tagged: abiraterone, cabazitaxel, cost, NICE, UK | 2 Comments »
A new “mini-review” in BJU International provides a summary overiew of the “economic burden” of prostate cancer, largely based on data from the “western” nations (inclusive of Europe, North America, and Australasia).
Filed under: Living with Prostate Cancer | Tagged: burden, cost, economic | Leave a Comment »
Sometimes it is difficult to know what to make of data from even the most reputable institutions. This appears to be the case for a recent study from a Harvard research team.
Filed under: Living with Prostate Cancer | Tagged: cancer, cost, drug coverage, Medicare, non-adherence | Leave a Comment »
Three new articles in the June 15 issue of Oncology review the current data and the potential of proton beam radiation therapy (PBRT) as a first-line treatment for localized prostate cancer. The full texts of all three articles are available on line.
Filed under: Management, Treatment | Tagged: cost, lozalized, outcome, PBRT, proton beam, radiation therapy | 5 Comments »
Many prostate cancer patients and advocates will want to read yesterday’s article by New York Times correspondent Andrew Pollack entitled, “New drugs fight prostate cancer, but at high cost.” The article offers a commentary on recent advances in the treatment of advanced prostate cancer — and the economic consequences.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: advanced, cost, drugs | Comments Off
Paul Levy is the President and CEO of the Beth Israel Deaconess Medical Center in Boston (which is no small institution). He is not an enthusiastic advocate for the sudden growth in the number of proton beam radiation therapy (PBRT) centers in the US in the past 3 years. You want to see why, just [...]
Filed under: Management, Treatment | Tagged: cost, outcome, PBRT, proton, radiation therapy | Comments Off
Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: appropriate use, cost, finance, incentive, LHRH agonist, Medicare | 3 Comments »
A common topic of discussion among some members of the patient and patient advocacy community is whether recommended management of prostate cancer for individual patients is driven by the potential revenue available to physicians and hospitals from differing recommendations.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, low risk, Management, revenue, Treatment | 7 Comments »
According to a media release from the American Cancer Society, a paper newly published online in Cancer suggests that some treatments for prostate cancer that are relatively low cost in the short term (i.e., in the first 12 months after treatment) may have higher costs over 5 years.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 1 year, 5 years, cost, Treatment | 6 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site